Secukinumab in the Treatment of Palmoplantar, Nail, Scalp, and Pustular Psoriasis.
作者信息
Armstrong April W, Vender Ron, Kircik Leon
机构信息
University of Southern California, Los Angeles, California.
Dermatrials Research Inc. and Venderm Innovations in Psoriasis, Hamilton, Ontario, Canada.
出版信息
J Clin Aesthet Dermatol. 2016 Jun;9(6 Suppl 1):S12-S16. Epub 2016 Jun 1.
Abstract
摘要
相似文献
1
Secukinumab in the Treatment of Palmoplantar, Nail, Scalp, and Pustular Psoriasis.司库奇尤单抗治疗掌跖、指甲、头皮及脓疱型银屑病
J Clin Aesthet Dermatol. 2016 Jun;9(6 Suppl 1):S12-S16. Epub 2016 Jun 1.
2
The Efficacy of Biologic Therapy for the Management of Palmoplantar Psoriasis and Palmoplantar Pustulosis: A Systematic Review.生物疗法治疗掌跖银屑病和掌跖脓疱病的疗效：一项系统评价
Dermatol Ther (Heidelb). 2017 Dec;7(4):425-446. doi: 10.1007/s13555-017-0207-0. Epub 2017 Nov 15.
3
Real world data from the use of secukinumab in the treatment of moderate-to-severe psoriasis, including scalp and palmoplantar psoriasis: A 104-week clinical study.使用司库奇尤单抗治疗中重度银屑病（包括头皮和掌跖部银屑病）的真实世界数据：一项 104 周的临床研究。
Dermatol Ther. 2019 Sep;32(5):e13006. doi: 10.1111/dth.13006. Epub 2019 Jul 15.
4
Secukinumab is effective in the treatment of recalcitrant palmoplantar psoriasis and palmoplantar pustular psoriasis in a daily practice setting.在日常临床实践中，司库奇尤单抗对治疗顽固性掌跖银屑病和掌跖脓疱型银屑病有效。
J Am Acad Dermatol. 2022 Sep;87(3):705-709. doi: 10.1016/j.jaad.2022.05.047. Epub 2022 May 28.
5
Secukinumab for moderate-to-severe palmoplantar pustular psoriasis: Results of the 2PRECISE study.司库奇尤单抗治疗中重度掌跖脓疱型银屑病：2PRECISE 研究结果。
J Am Acad Dermatol. 2019 May;80(5):1344-1352. doi: 10.1016/j.jaad.2019.01.066. Epub 2019 Feb 1.
6
Rapid response to secukinumab in a 5-year-old with deficiency of the interleukin-36 receptor antagonist (DITRA) with severe scalp and nail involvement.5 岁患儿因白细胞介素-36 受体拮抗剂（DITRA）缺乏导致严重头皮和指甲受累，使用司库奇尤单抗后迅速起效。
Pediatr Dermatol. 2021 Sep;38(5):1258-1263. doi: 10.1111/pde.14737. Epub 2021 Aug 2.
7
Similarity and difference between palmoplantar pustulosis and pustular psoriasis.掌跖脓疱病与脓疱型银屑病的异同。
J Dermatol. 2021 Jun;48(6):750-760. doi: 10.1111/1346-8138.15826. Epub 2021 Mar 2.
8
Recalcitrant annular pustular psoriasis associated with psoriatic arthritis successfully treated with secukinumab.司库奇尤单抗成功治疗与银屑病关节炎相关的顽固性环状脓疱型银屑病。
JAAD Case Rep. 2018 Sep 19;4(8):842-844. doi: 10.1016/j.jdcr.2018.03.016. eCollection 2018 Sep.
9
Palmoplantar pustular psoriasis (PPPP) is characterized by activation of the IL-17A pathway.掌跖脓疱型银屑病（PPPP）的特征是白细胞介素-17A通路的激活。
J Dermatol Sci. 2017 Jan;85(1):20-26. doi: 10.1016/j.jdermsci.2016.09.019. Epub 2016 Sep 29.
10
Sustained High Efficacy and Favorable Safety Over Five Years in Patients With Burdensome Psoriasis (UNCOVER-1/UNCOVER-2).UNCOVER-1/UNCOVER-2 研究：中重度斑块状银屑病患者五年持续高疗效且安全性良好
J Drugs Dermatol. 2021 Aug 1;20(8):880-887. doi: 10.36849/JDD.6101.
引用本文的文献
1
Effectiveness and safety of secukinumab updosing in patients with moderate to severe plaque psoriasis: data from the PURE registry.司库奇尤单抗剂量递增治疗中重度斑块状银屑病患者的疗效和安全性：来自 PURE 登记研究的数据。
Arch Dermatol Res. 2024 Jun 8;316(7):362. doi: 10.1007/s00403-024-03122-w.
2
Lower Limbs are the Most Difficult-to-Treat Body Region of Patients with Psoriasis: Pooled Analysis of CLEAR and CLARITY Studies of Secukinumab Versus Ustekinumab by Body Region.下肢是银屑病患者最难治疗的身体部位：司库奇尤单抗与乌司奴单抗治疗不同身体部位的 CLEAR 和 CLARITY 研究的汇总分析。
BioDrugs. 2022 Nov;36(6):781-789. doi: 10.1007/s40259-022-00558-2. Epub 2022 Nov 5.
3
Narrative Review of the Emerging Therapeutic Role of Brodalumab in Difficult-to-Treat Psoriasis.布罗达单抗在难治性银屑病中新兴治疗作用的叙述性综述
Dermatol Ther (Heidelb). 2022 Jun;12(6):1289-1302. doi: 10.1007/s13555-022-00746-6. Epub 2022 Jun 7.
4
Long-term Safety of Secukinumab Over Five Years in Patients with Moderate-to-severe Plaque Psoriasis, Psoriatic Arthritis and Ankylosing Spondylitis: Update on Integrated Pooled Clinical Trial and Post-marketing Surveillance Data.司库奇尤单抗治疗中重度斑块状银屑病、银屑病关节炎和强直性脊柱炎患者五年的长期安全性：汇总临床试验和上市后监测数据的更新。
Acta Derm Venereol. 2022 Apr 27;102:adv00698. doi: 10.2340/actadv.v102.563.
5
Real-World Satisfaction with Secukinumab in Clearing the Skin of Patients with Plaque Psoriasis through 24 Months of Follow-Up: Results from US Dermatology Electronic Medical Records.通过24个月随访观察司库奇尤单抗清除斑块状银屑病患者皮肤的真实世界满意度：来自美国皮肤科电子病历的结果
Dermatol Ther (Heidelb). 2021 Oct;11(5):1733-1749. doi: 10.1007/s13555-021-00599-5. Epub 2021 Aug 28.
6
Toenail Psoriasis during Ustekinumab Therapy: Results and Limitations.优特克单抗治疗期间的趾甲银屑病：结果与局限性
Ann Dermatol. 2021 Apr;33(2):131-137. doi: 10.5021/ad.2021.33.2.131. Epub 2021 Mar 8.
7
Interleukin-17 and Interleukin-23: A Narrative Review of Mechanisms of Action in Psoriasis and Associated Comorbidities.白细胞介素-17与白细胞介素-23：银屑病及其相关合并症作用机制的叙述性综述
Dermatol Ther (Heidelb). 2021 Apr;11(2):385-400. doi: 10.1007/s13555-021-00483-2. Epub 2021 Jan 29.
8
Secukinumab Improves Patient Perception of Anxiety and Depression in Patients with Moderate to Severe Psoriasis: A Post hoc Analysis of the SUPREME Study.司库奇尤单抗改善中重度银屑病患者的焦虑和抑郁：SUPREME 研究的事后分析。
Acta Derm Venereol. 2021 Mar 31;101(3):adv00422. doi: 10.2340/00015555-3712.
9
IgA vasculitis during secukinumab therapy.司库奇尤单抗治疗期间发生的 IgA 血管炎。
Clin Rheumatol. 2021 May;40(5):2071-2073. doi: 10.1007/s10067-020-05364-1. Epub 2020 Aug 29.
10
Characterization of Patients with Psoriasis in Challenging-to-Treat Body Areas in the Corrona Psoriasis Registry.在 Corrona 银屑病注册研究中，对治疗困难的身体部位银屑病患者的特征进行描述。
Dermatology. 2021;237(1):46-55. doi: 10.1159/000504841. Epub 2020 Jan 21.
本文引用的文献
1
Topical treatments for scalp psoriasis.头皮银屑病的局部治疗
Cochrane Database Syst Rev. 2016 Feb 26;2(2):CD009687. doi: 10.1002/14651858.CD009687.pub2.
2
Apremilast, an oral phosphodiesterase 4 inhibitor, in patients with difficult-to-treat nail and scalp psoriasis: Results of 2 phase III randomized, controlled trials (ESTEEM 1 and ESTEEM 2).阿普米司特，一种口服磷酸二酯酶 4 抑制剂，用于治疗难治性指甲和头皮银屑病患者：两项 III 期随机对照试验（ESTEEM 1 和 ESTEEM 2）的结果。
J Am Acad Dermatol. 2016 Jan;74(1):134-42. doi: 10.1016/j.jaad.2015.09.001.
3
Secukinumab in plaque psoriasis--results of two phase 3 trials.司库奇尤单抗治疗斑块状银屑病的两项 3 期临床试验结果。
N Engl J Med. 2014 Jul 24;371(4):326-38. doi: 10.1056/NEJMoa1314258. Epub 2014 Jul 9.
4
Palmoplantar psoriasis is associated with greater impairment of health-related quality of life compared with moderate to severe plaque psoriasis.与中度至重度斑块状银屑病相比，掌跖银屑病与健康相关生活质量的更大损害相关。
J Am Acad Dermatol. 2014 Oct;71(4):623-32. doi: 10.1016/j.jaad.2014.04.063. Epub 2014 Jun 2.
5
Adalimumab for the treatment of moderate to severe psoriasis: subanalysis of effects on scalp and nails in the BELIEVE study.阿达木单抗治疗中重度银屑病：BELIEVE研究中对头皮和指甲影响的亚组分析。
J Eur Acad Dermatol Venereol. 2015 Feb;29(2):353-360. doi: 10.1111/jdv.12553. Epub 2014 May 21.
6
Topical treatments for chronic plaque psoriasis of the scalp: a systematic review.头皮慢性斑块状银屑病的局部治疗：系统评价。
Br J Dermatol. 2013 Sep;169(3):519-27. doi: 10.1111/bjd.12393.
7
Nail psoriasis - a treatment challenge.甲银屑病——一种治疗挑战。
J Dtsch Dermatol Ges. 2013 Mar;11(3):203-19; quiz 220. doi: 10.1111/ddg.12054.
8
Secukinumab induction and maintenance therapy in moderate-to-severe plaque psoriasis: a randomized, double-blind, placebo-controlled, phase II regimen-finding study.司库奇尤单抗诱导和维持治疗中重度斑块状银屑病：一项随机、双盲、安慰剂对照、Ⅱ期方案探索研究。
Br J Dermatol. 2013 Feb;168(2):402-11. doi: 10.1111/bjd.12112.
9
Long-term safety of ustekinumab in patients with moderate-to-severe psoriasis: final results from 5 years of follow-up.乌司奴单抗治疗中重度斑块状银屑病患者的长期安全性：5 年随访的最终结果。
Br J Dermatol. 2013 Apr;168(4):844-54. doi: 10.1111/bjd.12214.
10
Effect of IL-17A blockade with secukinumab in autoimmune diseases.司库奇尤单抗阻断白介素-17A 在自身免疫性疾病中的作用。
Ann Rheum Dis. 2013 Apr;72 Suppl 2:ii116-23. doi: 10.1136/annrheumdis-2012-202371. Epub 2012 Dec 19.
Zotero 插件